Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial
Yoshimasa Shiraishi,Shogo Nomura,Shunichi Sugawara,Hidehito Horinouchi,Yasuto Yoneshima,Hidetoshi Hayashi,Koichi Azuma,Satoshi Hara,Seiji Niho,Ryo Morita,Masafumi Yamaguchi,Toshihide Yokoyama,Kiyotaka Yoh,Takayasu Kurata,Hiroaki Okamoto,Masaki Okamoto,Takashi Kijima,Kazuo Kasahara,Yutaka Fujiwara,Shuji Murakami,Shintaro Kanda,Hiroaki Akamatsu,Shinnosuke Takemoto,Hiroyasu Kaneda,Toshiyuki Kozuki,Masahiko Ando,Yuta Sekino,Haruhiko Fukuda,Yuichiro Ohe,Isamu Okamoto
DOI: https://doi.org/10.1016/s2213-2600(24)00185-1
IF: 102.642
2024-08-19
The Lancet Respiratory Medicine
Abstract:Summary Background The combination of platinum-based chemotherapy and an antibody to PD-1 or to its ligand PD-L1, with or without an antibody to CTLA-4, has improved the survival of individuals with metastatic non-small-cell lung cancer (NSCLC). However, no randomised controlled trial has evaluated the survival benefit of adding a CTLA-4 inhibitor to platinum-based chemotherapy plus a PD-1 or PD-L1 inhibitor. Methods This open-label, randomised, phase 3 trial was conducted at 48 hospitals in Japan. Eligible patients were aged 20 years or older with previously untreated advanced NSCLC and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients with known driver oncogenes were excluded. Participants were randomly assigned (1:1) to receive platinum-based chemotherapy (four cycles) plus pembrolizumab (pembrolizumab group) or platinum-based chemotherapy (two cycles) plus nivolumab–ipilimumab (nivolumab–ipilimumab group). The primary endpoint was overall survival and assessed in all randomly assigned patients on an intention-to-treat basis. The trial is registered in the Japan Registry for Clinical Trials, jRCTs031210013, and is now closed to new enrolment and is ongoing. Findings Between patient accrual initiation on April 6, 2021, and discontinuation of the trial on March 30, 2023, 11 (7%) of 148 patients in the nivolumab–ipilimumab group had a treatment-related death. Because of the high number of treatment-related deaths, patient accrual was terminated early, resulting in 295 patients (236 [80%] male and 59 [20%] female) enrolled; the primary analysis was done on the basis of 117 deaths (fewer than the required 329 deaths). By May 25, 2023 (data cutoff), overall survival did not differ significantly between the nivolumab–ipilimumab group and the pembrolizumab group (median 23·7 months [95% CI 17·6–not estimable] vs 20·5 months [17·6–not estimable], respectively; hazard ratio 0·98 [90% CI 0·72–1·34]; p=0·46). Non-haematological adverse events of grade 3 or worse occurred in 87 (60%) of 146 patients in the nivolumab–ipilimumab group and 59 (41%) of 144 patients in the pembrolizumab group. The pembrolizumab group tended to have a better quality of life compared with the nivolumab–ipilimumab group. Interpretation The safety and efficacy data suggest an unfavourable benefit–risk profile for nivolumab–ipilimumab combined with platinum-based chemotherapy relative to pembrolizumab combined with platinum-based chemotherapy as a first-line treatment for patients with advanced NSCLC, although a definitive conclusion awaits an updated analysis of overall survival. Funding The National Cancer Center Research and Development Fund and Japan Agency for Medical Research and Development.
respiratory system,critical care medicine